Literature DB >> 15641156

Plasma interleukin-18 reflects severity of ulcerative colitis.

Alicja Wiercinska-Drapalo1, Robert Flisiak, Jerzy Jaroszewicz, Danuta Prokopowicz.   

Abstract

AIM: The aim of this study was to evaluate the association between ulcerative colitis activity and plasma or mucosal concentrations of interleukin (IL)-18.
METHODS: Il-18 concentrations were measured in plasma and mucosal samples from 15 patients with active ulcerative colitis (UC).
RESULTS: The mean plasma concentration of IL-18 measured in all patients (422+/-88 pg/mL) doubled the mean value in healthy controls (206+/-32 pg/mL); however, the difference was not statistically significant. Plasma IL-18 levels revealed a significant positive correlation with scored endoscopic degree of mucosal injury, disease activity index, clinical activity index and C-reactive protein concentration. The mean concentration of plasma IL-18 was significantly higher in patients with severe ulcerative colitis (535+/-115 pg/mL) than in patients with mild ulcerative colitis (195+/-41 pg/mL), and in healthy controls. Although the mucosal mean IL-18 concentration in severe ulcerative colitis (2 523+/-618 pg/mg protein) doubled values observed in mild one (1 347+/-308 pg/mg protein), there was no statistically significant difference.
CONCLUSION: Plasma IL-18 can be considered as a surrogate marker helpful in evaluation of ulcerative colitis activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15641156      PMCID: PMC4250821          DOI: 10.3748/wjg.v11.i4.605

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

Review 1.  The role of Th1/Th2 polarization in mucosal immunity.

Authors:  Markus F Neurath; Susetta Finotto; Laurie H Glimcher
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 2.  Transforming growth factor beta signaling mediators and modulators.

Authors:  C M Zimmerman; R W Padgett
Journal:  Gene       Date:  2000-05-16       Impact factor: 3.688

3.  Effect of ulcerative colitis treatment on transforming growth factor beta(1) in plasma and rectal mucosa.

Authors:  Alicja Wiercińska-Drapało; Robert Flisiak; Danuta Prokopowicz
Journal:  Regul Pept       Date:  2003-05-15

4.  Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.

Authors:  B Siegmund; G Fantuzzi; F Rieder; F Gamboni-Robertson; H A Lehr; G Hartmann; C A Dinarello; S Endres; A Eigler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-10       Impact factor: 3.619

5.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

6.  Serum interleukin-18 concentrations in patients with inflammatory bowel disease.

Authors:  Daisuke Furuya; Atsuhito Yagihashi; Momoko Komatsu; Nakamura Masashi; Naoki Tsuji; Daisuke Kobayashi; Naoki Watanabe
Journal:  J Immunother       Date:  2002 Mar-Apr       Impact factor: 4.456

Review 7.  Growth factors in inflammatory bowel disease.

Authors:  P L Beck; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  1999-02       Impact factor: 5.325

8.  Differential expression of CCR5 and CRTH2 on infiltrated cells in colonic mucosa of patients with ulcerative colitis.

Authors:  Koji Matsuzaki; Ryota Hokari; Shingo Kato; Yoshikazu Tsuzuki; Hirofumi Tanaka; Chie Kurihara; Atsuhiro Iwai; Atsushi Kawaguchi; Shigeaki Nagao; Kazuro Itoh; Kinya Nagata; Soichiro Miura
Journal:  J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 4.029

9.  Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice.

Authors:  Takahiro Ishikura; Takanori Kanai; Koji Uraushihara; Ryoichi Iiyama; Shin Makita; Teruji Totsuka; Motomi Yamazaki; Taisuke Sawada; Tetsuya Nakamura; Tatsuya Miyata; Tetsuji Kitahora; Toshifumi Hibi; Tomoaki Hoshino; Mamoru Watanabe
Journal:  J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 4.029

10.  Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.

Authors:  Yoshinori Sawa; Nobuhide Oshitani; Kenji Adachi; Kazuhide Higuchi; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Int J Mol Med       Date:  2003-02       Impact factor: 4.101

View more
  7 in total

Review 1.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

2.  Dissemination of invasive Salmonella via bacterial-induced extrusion of mucosal epithelia.

Authors:  Leigh A Knodler; Bruce A Vallance; Jean Celli; Seth Winfree; Bryan Hansen; Marinieve Montero; Olivia Steele-Mortimer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

3.  Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets.

Authors:  Dina Montufar-Solis; Heuy-Ching Wang; John R Klein
Journal:  J Leukoc Biol       Date:  2007-08-16       Impact factor: 4.962

4.  Prointerleukin-18 is activated by meprin beta in vitro and in vivo in intestinal inflammation.

Authors:  Sanjita Banerjee; Judith S Bond
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

5.  Serum interleukin-1 receptor antagonist is an early indicator of colitis onset in Galphai2-deficient mice.

Authors:  O H Hultgren; M Berglund; M Bjursten; E Hultgren Hörnquist
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

6.  Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis.

Authors:  Yunliang Wang; Lijuan Liu; Yi Guo; Tangyou Mao; Rui Shi; Junxiang Li
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

7.  The mRNA level of the transforming growth factor β1 gene, but not the amount of the gene product, can be considered as a potential prognostic parameter in inflammatory bowel diseases in children.

Authors:  Anna Liberek; Zbigniew Kmieć; Dorota Kartanowicz; Piotr M Wierzbicki; Marcin Stanisławowski; Lucyna Kaszubowska; Grażyna Luczak; Magdalena Góra-Gębka; Piotr Landowski; Agnieszka Szlagatys-Sidorkiewicz; Tomasz Liberek; Barbara Kamińska; Joanna Jakóbkiewicz-Banecka; Grzegorz Węgrzyn
Journal:  Int J Colorectal Dis       Date:  2012-05-15       Impact factor: 2.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.